Be Biopharma, an innovative leader in the realm of Engineered B Cell Medicines (BCMs), has successfully raised $82 million in a recent funding round aimed at transforming the therapeutic landscape for patients with Hemophilia B and various genetic diseases, alongside addressing critical medical challenges related to cancer and other serious conditions. This substantial investment underscores the growing investor confidence in Be Bio's unique approach to developing cutting-edge cell therapies designed with the patient at their core. The funds will be strategically allocated to accelerate the ongoing research and development of BCM technology, enabling the company to advance clinical trials that will bring these groundbreaking treatments closer to market. A dedicated team comprised of passionate scientists, skilled technologists, and experienced business builders are collaborating to unlock the potential of engineered B cell therapies, which harness the power of the immune system to create durable and effective solutions. The implications of this funding are profound, as it paves the way for Be Bio to enhance its manufacturing capabilities and expand its operational framework, ultimately aiming to improve countless lives affected by debilitating conditions. As Be Biopharma continues to lead the charge in pioneering cellular innovations, this funding round marks a significant step forward in their mission to redefine how we approach treatment in genetic diseases and hematological disorders, offering hope to patients and their families worldwide.
Be Biopharma Secures $82 Million Funding for Advancing Engineered B Cell Medicines
Recently funded 路 $82.0MBiotechnology
Get the full Be Biopharma company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
